HCA Healthcare price target raised to $345 from $320 at Truist

Truist raised the firm’s price target on HCA Healthcare to $345 from $320 and keeps a Buy rating on the shares. The company reported better than expected Q4 results driven by solid volume trends, effective cost controls, strong cash flows, upbeat guidance and a dividend raise, the analyst tells investors in a research note. Truist adds that commentary around utilization and volumes remains encouraging, while labor trends “continue to improve”.